Other Clinical Trial - Durvalumab & SNDX-6532 Following Chemo or

Updated 04/23/2024

Status Completed

Clinical Trial Summary

The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cholangiocarcinoma
Unresectable Intrahepatic Cholangiocarcinoma

Clinical Trial Details

NCT number	NCT04301778
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact
Status	Completed
Phase	Phase 2
Start date	August 24, 2021
Completion date	February 6, 2024

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03942328` - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	Phase 1/Phase 2
	Terminated	`NCT02256982` - A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma	N/A
	Not yet recruiting	`NCT06058663` - Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	Phase 1
	Active, not recruiting	`NCT04175912` - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	Phase 2
	Recruiting	`NCT05738057` - Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma	Phase 2
	Terminated	`NCT02994251` - A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma	Phase 2
	Completed	`NCT01648023` - Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin	Phase 2
	Recruiting	`NCT05564403` - Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	Phase 2
	Active, not recruiting	`NCT03768414` - Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers	Phase 3
	Active, not recruiting	`NCT04251715` - mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma	Phase 2